

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-64. (Canceled)

65. (Previously added) An isolated polypeptide comprising SEQ ID NO:525.

66-73. (Canceled)

74. (Previously added) A composition comprising an immunostimulant and an isolated polypeptide comprising SEQ ID NO: 525, wherein the polypeptide contains an amino acid sequence capable of stimulating human T-cells.

75. (Currently amended) A composition comprising an immunostimulant and an isolated polypeptide comprising at least the T-cell epitope of amino acids 1-39 112-120 of SEQ ID NO: 525, wherein the polypeptide contains an amino acid sequence capable of stimulating human T cells wherein the immunostimulant induces a predominantly Th1-type response.

76. (Canceled)

77. (Currently amended) The composition according to any one of claims ~~72-76~~74-75, wherein the immunostimulant is selected from the group consisting of a monophosphoryl lipid A, a CpG-containing oligonucleotide, a saponin, or a combination thereof.

78. (Currently amended) The composition according to any one of claims ~~72-76~~74-75, wherein the immunostimulant is selected from the group consisting of 3D-MPL, QS21, or a combination thereof.

79. (Currently amended) The composition according to any one of claims ~~72-76~~74-75, wherein the immunostimulant comprises 3D-MPL, QS21 and tocopherol in an oil-in-water emulsion.